- Cuprina Holdings (CUPR, Financial) has successfully raised $13.8 million in total gross proceeds through its IPO and over-allotment option.
- The full exercise of the over-allotment option indicates strong initial investor interest.
- The IPO consisted of selling an additional 450,000 Class A ordinary shares at $4.00 each.
Cuprina Holdings (NASDAQ: CUPR), a biomedical and biotechnology company, has announced the successful closing of its underwriter's over-allotment option. This move follows its initial public offering (IPO), which resulted in the sale of an additional 450,000 Class A ordinary shares at $4.00 per share.
The total gross proceeds from the offering, including this over-allotment, reached $13.8 million. The IPO was managed by R. F. Lafferty & Co., which acted as the sole book-running manager for the offering.
Cuprina Holdings focuses its efforts on developing products in the fields of chronic wound management, infertility treatments, and cosmeceuticals for the health and beauty sector. The company's IPO was executed under the Form F-1 registration statement, declared effective by the U.S. Securities and Exchange Commission on March 31, 2025.
